Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
Status:
Completed
Trial end date:
2014-12-05
Target enrollment:
Participant gender:
Summary
This study will assess safety, antiviral activity, and pharmacokinetics of different doses of
maribavir administered orally for up to 24 weeks for treatment of CMV infections that are
resistant or refractory to treatment with ganciclovir/valganciclovir or foscarnet in
recipients of stem cell or solid organ transplants.